Oxford Asset Management’s Altimmune ALT Stock Holding History

Oxford Asset Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-84,870	Closed	-$175K	–	1637
2018 Q4	$175K	Buy	+84,870	New	+$300K	﹤0.01%	1568
2017 Q4	–	Sell	-2,367	Closed	-$165K	–	1601
2017 Q3	$165K	Sell	2,367 -675	-22%	-$50.2K	﹤0.01%	1443
2017 Q2	$292K	Sell	3,042 -685	-18%	-$114K	0.01%	1267
2017 Q1	$907K	Buy	3,727 +1,973	+112%	+$1.06M	0.02%	849
2016 Q4	$1.71M	Buy	1,754 +1,617	+1,180%	+$1.45M	0.06%	368
2016 Q3	$120K	Buy	137 +89	+185%	+$69.8K	﹤0.01%	730
2016 Q2	$35K	Buy	+48	New	+$32.8K	﹤0.01%	764
2015 Q2	–	Sell	-66	Closed	-$33K	–	653
2015 Q1	$33K	Sell	66 -31	-32%	-$15.4K	﹤0.01%	652
2014 Q4	$51K	Buy	+97	New	+$49.8K	﹤0.01%	676
2014 Q2	–	Sell	-327	Closed	-$179K	–	684
2014 Q1	$179K	Sell	327 -118	-27%	-$68.9K	0.01%	597
2013 Q4	$248K	Hold	445	–	–	0.01%	637
2013 Q3	$280K	Hold	445	–	–	0.01%	710
2013 Q2	$212K	Buy	+445	New	+$221K	0.01%	785

Other funds holding ALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oxford Asset Management's ALT Position: Q1 2019 in Review

Oxford Asset Management sold out of Altimmune (ALT) in Q1 2019, closing a stake of 84,870 shares — an estimated $175K sold.

Oxford Asset Management first reported a position in ALT in Q2 2013 and held it in 13 quarters. The position peaked at $1.71M in Q4 2016. 21 funds tracked by Wall St. Rank hold ALT as of Q1 2019.

Oxford Asset Management reported no remaining Altimmune position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 84,870 Altimmune shares in Q1 2019, an estimated $175K.
Oxford Asset Management first reported a position in Altimmune in Q2 2013 and held it in 13 quarters.
Oxford Asset Management's Altimmune position peaked at $1.71M in Q4 2016.
21 funds tracked by Wall St. Rank held Altimmune as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.